Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection.

IF 6.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Current Diabetes Reports Pub Date : 2025-09-26 DOI:10.1007/s11892-025-01606-1

Iciar Aviles-Olmos, Christian Espinoza-Vinces, Leyre Rogel Portugal, María Rosario Luquin

{"title":"Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection.","authors":"Iciar Aviles-Olmos, Christian Espinoza-Vinces, Leyre Rogel Portugal, María Rosario Luquin","doi":"10.1007/s11892-025-01606-1","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinson's disease (PD), focusing on body weight regulation and neuroprotection.Recent findings: GLP-1 RAs modulate insulin signaling, reduce neuroinflammation and oxidative stress, and improve mitochondrial functional mechanisms linked to neuroprotection. Clinical trials show modest but sustained improvements in motor symptoms and suggest benefits in cognition, mood, and apathy. While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited. However, individuals with obesity or insulin resistance may experience enhanced clinical and cognitive outcomes. GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction. Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"49"},"PeriodicalIF":6.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474678/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-025-01606-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinson's disease (PD), focusing on body weight regulation and neuroprotection.

Recent findings: GLP-1 RAs modulate insulin signaling, reduce neuroinflammation and oxidative stress, and improve mitochondrial functional mechanisms linked to neuroprotection. Clinical trials show modest but sustained improvements in motor symptoms and suggest benefits in cognition, mood, and apathy. While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited. However, individuals with obesity or insulin resistance may experience enhanced clinical and cognitive outcomes. GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction. Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.

Abstract Image

查看原文本刊更多论文

针对帕金森病代谢功能障碍：GLP-1激动剂在体重调节和神经保护中的作用

综述目的：本文综述了GLP-1受体激动剂（GLP-1 RAs）在帕金森病（PD）代谢功能障碍和神经退行性变中的作用，重点是体重调节和神经保护。最近的研究发现：GLP-1 RAs调节胰岛素信号，减少神经炎症和氧化应激，并改善与神经保护相关的线粒体功能机制。临床试验显示运动症状有适度但持续的改善，并提示在认知、情绪和冷漠方面有益处。虽然GLP-1 RAs可诱导糖尿病患者体重减轻，但其对血糖正常的PD患者的代谢影响似乎有限。然而，肥胖或胰岛素抵抗的个体可能会经历更高的临床和认知结果。GLP-1 RAs为PD提供了多方面的治疗策略，既针对中枢神经退行性过程，也针对外周代谢功能障碍。它们在疾病改变和症状缓解方面的潜力，特别是在特定表型方面，支持它们作为个性化治疗方法的一部分进行进一步探索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.